ArticleCureus2025
Effects of Intravenous Thiopentone Versus Etomidate on Modified Electroconvulsive Therapy (MECT) in Patients With Major Depressive Disorder.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Electroconvulsive therapy (ECT) has a well-established role in the management of patients who do not respond to psychopharmacological treatment. The therapeutic effect of ECT on major depressive disorder is widely investigated; the search for an ideal induction agent for ECT is an ongoing process. The present study was conducted to compare the effects of 3 mg/kg of intravenous thiopentone versus 0.2 mg/kg of intravenous etomidate on modified electroconvulsive therapy (MECT) in patients with major depressive disorder. Methods The present study was carried out as a double-blinded randomized study on 40 patients diagnosed with major depressive disorder. The study was approved by the institutional ethics committee, and written informed consent from each patient was obtained before the study. A total of 40 patients were divided into two groups of 20 each by block randomization. Group A patients (n = 20) received IV etomidate 0.2 mg/kg. Group B (n = 20) patients received IV thiopentone 3 mg/kg. After induction and muscle relaxation, electrical stimulus was applied, and the duration of seizure quality was measured using the cuff method. Results All statistical tests were done with IBM SPSS Statistics for Windows, Version 24 (Released 2016; IBM Corp., Armonk, New York, United States). The average seizure duration was 54 seconds in group A (etomidate), and it was 42 seconds in group B (thiopentone). Etomidate showed longer seizure duration compared to thiopentone with a significant p-value of 0.001 using an independent-samples T-test. Conclusion Etomidate, as an induction agent for patients with major depressive disorder, showed good seizure quality compared to thiopentone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.